Progress and limitations of new treatments

We are entering an exciting era for treating neurodegenerative diseases, with a new wave of promising antibody-based products targeting amyloid beta reaching Alzheimer’s patients.

Despite high expectations, these treatments are likely to have limited impact, as they target only one misfolded protein. Amyloid-mediated diseases often involve multiple proteins, such as amyloid beta, tau, and alpha-synuclein. Companies are aware of these limitations and are already testing antibody combinations.